The unhealthy state of health policy research

Health Affairs

Volumn 28, Issue 5, 2009, Pages

  Majumdar, Sumit R ^a   Soumerai, Stephen B ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST CONTROL; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; INFORMATION TECHNOLOGY; MEDICAL FEE; MEDICAL INFORMATION; NOTE; RISK BENEFIT ANALYSIS;

FORMULARIES AS TOPIC; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; RESEARCH DESIGN; UNITED STATES;

EID: 70349200999     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.5.w900     Document Type: Note

References (46)

1. J.P. Newhouse et al., "Some Interim Results from a Controlled Trial of Cost Sharing in Health Insurance," New England Journal of Medicine 305, no.25 (1981): 1501-1507;
2. and S.B. Soumerai et al., "Effects of a Limit on Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia," New England Journal of Medicine 331, no. 10 (1994): 650-655.
3. S.B. Soumerai et al., "Determinants of Change in Medicaid Pharmaceutical Cost-Sharing: Does Evidence Affect Policy?" Milbank Quarterly 75, no.1 (1997): 11-34;
4. and Agency for Healthcare Research and Quality case report, "National Alliance for the Mentally Ill: CP3 05-01 Research Prescription Drugs/Low-Income National" (Rockville, Md.: AHRQ, 2005).
5. S.B. Soumerai and D. Ross-Degnan, "Inadequate Prescription-Drug Coverage for Medicare Enrollees: A Call to Action," New England Journal of Medicine 340, no.9 (1999): 722-728.
6. Soumerai et al., "Determinants of Change."
7. A.K. Wagner et al., "Effect of New York State Regulatory Action on Benzodiazepine Prescribing and Hip Fracture Rates," Annals of Internal Medicine 146, no.2 (2007): 96-103.
8. Examples of studies using strong quasi-experimental design include W.A. Ray, J.R. Daugherty, and K.G. Meador, "Effect of a Mental Health 'Carve-Out' Program on the Continuity of Antipsychotic Therapy," New England Journal of Medicine 348, no.19 (2003): 1885-1894;
9. and R. Tamblyn et al., "Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons," Journal of the American Medical Association 285, no. 4 (2001): 421-429.
10. An example of conclusions based on flawed research designs is C.W. Cranor and D.B. Christensen, "The Asheville Project: Long-Term Clinical and Economic Outcomes of a Community Pharmacy Diabetes Care Program," Journal of the American Pharmaceutical Association 43, no. 2 (2003): 173-184.
11. D.T. Campbell and J.C. Stanley, Experimental and Quasi-Experimental Designs for Research (Chicago: Rand McNally, 1966).
12. R. Smith, "The Trouble with Medical Journals" (London: Royal Society of Medicine Press, 2006).
13. G. Taubes, "Epidemiology Faces Its Limits," Science 269, no.5221 (1995): 164-169.
14. J.R. Gilbert, R.J. Light, and F. Mosteller, "Assessing Social Innovations: An Empirical Base for Policy," in Evaluation and Experiment: Some Critical Issues in Assessing Social Programs, ed. C.H. Bennett and A.A. Lumsdaine (New York: Academic Press, 1975).
15. S. Hennessy et al., "Drug Utilization Review," in Pharmacoepidemiology, 4th ed., ed. B. Strom (Chichester, England: John Wiley and Sons, 2005).
16. R. Mannion and H. Davies, "Payment for Performance in Health Care,"BMJ336, no.7639 (2008): 306-308.
17. H. Sturmet al., "Pharmaceutical Policies: Effects of Financial Incentives for Prescribers," Cochrane Database of Systematic Reviews, Issue 3 (2007): CD006731.
18. M.B. Rosenthal, "Beyond Pay for Performance - Emerging Models of Provider-Payment Reform," New England Journal of Medicine 359, no.12 (2008): 1197-1200.
19. S.D. Horn et al., "Intended and Unintended Consequences of HMO Cost-Containment Strategies: Results from the Managed Care Outcomes Project," American Journal of Managed Care 2, no.3 (1996): 253-264.
20. D. Ross-Degnan and S.B. Soumerai,"HMO Formularies and Care Costs," Lancet347, no.9010 (1996): 1264.
21. J.E. Wennberg, "Understanding Geographic Variations in Health Care Delivery," New England Journal of Medicine 340, no.1 (1999): 52-53. (Pubitemid 29024687)
22. F.R. Curtiss, "Drug Formularies Provide a Path to Best Care," American Journal of Health-System Pharmacy 53, no.18 (1996): 2201-2203.
23. S.B. Soumerai, "Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid," Health Affairs 23, no.1 (2004): 135-146.
24. Cranor et al., "The Asheville Project."
25. Academy of Managed Care Pharmacy, "Sound Medication Therapy Management Programs: 2006 Consensus Document," 2006, http://www.amcp.org/ data/nav-content/websiteMTMdocument.pdf (accessed 24 July 2009).
26. Tamblyn et al., "Adverse Events."
27. C.Y. Lu et al., "Interventions Designed to Improve the Quality and Efficiency of Medication Use in Managed Care: A Critical Review of the Literature - 2001-2007," BMC Health Services Research 8 (2008): 75.
28. A.L. Hillman et al., "Financial Incentives and Drug Spending in Managed Care," Health Affairs 18, no.2 (1999): 189-200.
29. D. Rubin, "Estimating Causal Effects from Large Data Sets using Propensity Scores," Annals of Internal Medicine 127, no.8, Part 2 (1997): 757-763.
30. Lu et al., "Interventions Designed";
31. and J. Hsu et al., "Unintended Consequences of Caps on Medicare Drug Benefits," New England Journal of Medicine 354, no.22 (2006): 2349-2359.
32. R. Light, J. Singer, and J. Willett, By Design: Planning Research on Higher Education (Cambridge, Mass.: Harvard University Press, 1990).
33. B. Chaudhry et al., "Systematic Review: Impact of Health Information Technology on Quality, Efficiency, and Costs of Medical Care," Annals of Internal Medicine 144, no.10 (2006): 742-752.
34. B. Chaudhry et al., "Systematic Review: Impact of Health Information Technology on Quality, Efficiency, and Costs of Medical Care," Annals of Internal Medicine 144, no.10 (2006): 742-752.Ibid.
35. M. Eccles et al., "Effect of Computerised Evidence Based Guidelines on Management of Asthma and Angina in Adults in Primary Care: Cluster Randomised Controlled Trial," BMJ 325, no.7370 (2002): 941.
36. W.M. Tierney et al., "Effects of Computerized Guidelines for Managing Heart Disease in Primary Care," Journal of General Internal Medicine 18, no.12 (2003): 967-976;
37. and W.M. Tierney et al., "Can Computer-Generated Evidence-Based Care Suggestions Enhance Evidence-Based Management of Asthma and Chronic Obstructive Pulmonary Disease? A Randomized, Controlled Trial," Health Services Research 40, no. 2 (2005): 477-497.
38. K. Davis, "Investing in Health Care Reform," New England Journal of Medicine 360, no.9 (2009): 852-855.
39. W.R. Shadish, T.D. Cook, and D.T. Campbell, Experimental and Quasi-Experimental Designs for Generalized Causal Inference (Boston: Houghton Mifflin Company, 2002).
40. Ibid.W.R. Shadish, T.D. Cook, and D.T. Campbell, Experimental and Quasi-Experimental Designs for Generalized Causal Inference 2002).
41. A.K. Wagner et al., "Segmented Regression Analysis of Interrupted Time Series Studies in Medication Use Research," Journal of Clinical Pharmacy and Therapeutics 27, no.4 (2002): 299-309.
42. E.R. Tufte, The Visual Display of Quantitative Information, 2d ed. (Cheshire, Conn.: Graphics Press, 2001).
43. Wagner et al., "Effect of New York State Regulatory Action."
44. S.B. Soumerai et al., "Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes," New England Journal of Medicine 325, no.15 (1991): 1072-1077.
45. S. Schneeweiss et al., "Outcomes of Reference Pricing for Angiotensin-Converting-Enzyme Inhibitors," New England Journal of Medicine 346, no.11 (2002): 822-829;
46. and S. Schneeweiss et al., "Clinical and Economic Consequences of a Reimbursement Restriction of Nebulised Respiratory Therapy in Adults: Direct Comparison of Randomised and Observational Evaluations," BMJ 328, no. 7439 (2004): 560.